[13].Willeit P, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018 Oct 13;392(10155):1311-1320. [14].Bhatia HS, et al. Independence of Lipoprotein(a) and Low-...
CLD(cholesterol-lowering drug,usually a statin)-降胆固醇药物 2013 ACC/AHA血脂指南 药物调脂干预 人群 (汇总队列方程评估10年ASCVD风险 ) 1. 临床存在ASCVD者 3. 临床无ASCVD的糖尿病 ,年龄40-75岁,LDL– C 70-189mg/dL 者 2. 原发性LDL–C升高 ≥190 mg/dL者 4. 临床无ASCVD 或糖尿 病, LDL–...
we found that with an average baseline LDL level of 4.3 mmol/l for each of the statin cohorts, LDL reductions followed the sam 52、e pattern, being largest with rosuvastatin (48%), followed by atorvastatin (42%), simvastatin (39%) and pravastatin (32%). 这些研究结果与这些他汀能够达到的...
The proportion of days above target level for all four cohorts is described in Figure 1. Among 107,552 patients with recorded LDL-C levels 鈮 1.8mmol/L at their last visit/censor date, 30.9% were on statin monotherapy and 1.0% were on statin+ezetimibe. Statin use was highest in ASCVD ...
of Statin and Ezetimibe[J]. Adv Ther. 2021;38(10):5270-5285. [5] Bangalore S, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?[J]...
statin therapy and whose LDL-C level remains 70 mg/dL mmol/l orhigher, it may be reasonable to add ezetimibe ( 54 1-15)接受最大耐受他汀治疗的临床 ASCVD患者,如LDLc≥70mg/dl(≥18mmol),加入依折麦布可能是合理的grundy SM, et al. J Am Coll Cardiol. 2018 Nov 8 pii: S0735-1097(18)...
是适合中国人群的他汀142021年ASCVD他汀选择策略7/24/2023临床实践中不得不关注的话题7.1.SexandRacialandEthnicSubgroupsBecausetheRCTevidenceshowsthattheabsolutebenefitofstatintreatmentisproportionaltobaselineASCVDrisk,treatmentdecisionsforwomenandracialandethnicsubgroupsshouldbebasedonthelevelofASCVDrisk.2011年9月19-20...
While that’s a drawback, he noted that traditional risk calculators, such as the ACC/AHA pooled cohort equation, don’t have this level of evidence either. “At the end of the day, a lot of things we do in medicine don’t have all the evidence,” he said. In Europe, one ...
of Statin and Ezetimibe[J]. Adv Ther. 2021;38(10):5270-5285. [13] Bangalore S, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?[J].Am...
19. Puri R, Nissen S E, Ballantyne C M, et al. Factors underlying regression of coronary atheroma with potent statin therapy[J]. European Heart Journal, 2013, 34(24): 1818-1825. 20. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and at...